For every over-hyped technology in the biopharma sector, a lesson in humility never seems far behind. But it seems most can be traced back to a humbling reminder: Mother Nature has been conducting biotech research and development for nearly 4 billion years. Best to have her on your side.
Unfortunately for investors, there's some uncertainty to that allegiance when it comes to the use of CRISPR gene-editing techniques (ironically invented by Mother Nature as a bacterial immune system) in mammalian cells, such as those of human origin. Two separate research studies have shown that one of two techniques featured in the pipelines of all three medically focused commercializers of the technology could awaken faulty DNA repair mechanisms inside cells, increasing the probability they become cancerous.�
While it's easy to be dismissive of the CRISPR-cancer�connection or assume the problem will be solved down the road, a closer look at the issue hints that may not be such an easy feat. It could pose a problem for parts of the pipelines of Editas Medicine (NASDAQ:EDIT), Intellia Therapeutics (NASDAQ:NTLA), and CRISPR Therapeutics (NASDAQ:CRSP).
Top Biotech Stocks For 2019: DXP Enterprises Inc.(DXPE)
Advisors' Opinion:- [By Logan Wallace]
American Century Companies Inc. decreased its position in DXP Enterprises, Inc. (NASDAQ:DXPE) by 63.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 266,785 shares of the industrial products company’s stock after selling 454,667 shares during the quarter. American Century Companies Inc. owned approximately 1.54% of DXP Enterprises worth $10,391,000 at the end of the most recent reporting period.
- [By Joseph Griffin]
Get a free copy of the Zacks research report on DXP Enterprises (DXPE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Logan Wallace]
Dynamic Technology Lab Private Ltd purchased a new stake in DXP Enterprises Inc (NASDAQ:DXPE) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 10,421 shares of the industrial products company’s stock, valued at approximately $406,000.
Top Biotech Stocks For 2019: Broadwind Energy Inc.(BWEN)
Advisors' Opinion:- [By Ethan Ryder]
Matthews International (NASDAQ: MATW) and Broadwind Energy (NASDAQ:BWEN) are both small-cap consumer staples companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability and institutional ownership.
- [By Shane Hupp]
Matthews International (NASDAQ: MATW) and Broadwind Energy (NASDAQ:BWEN) are both small-cap consumer staples companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, profitability, risk, earnings and dividends.
Top Biotech Stocks For 2019: Camden Property Trust(CPT)
Advisors' Opinion:- [By Max Byerly]
Amundi Pioneer Asset Management Inc. lifted its holdings in Camden Property Trust (NYSE:CPT) by 8.0% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 291,582 shares of the real estate investment trust’s stock after acquiring an additional 21,627 shares during the period. Amundi Pioneer Asset Management Inc. owned approximately 0.31% of Camden Property Trust worth $24,545,000 as of its most recent filing with the Securities and Exchange Commission.
- [By Shane Hupp]
News articles about Camden Property Trust (NYSE:CPT) have trended positive recently, according to Accern. Accern scores the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Camden Property Trust earned a coverage optimism score of 0.29 on Accern’s scale. Accern also assigned media coverage about the real estate investment trust an impact score of 47.1765126263188 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
- [By Logan Wallace]
Cryptaur (CURRENCY:CPT) traded up 2.6% against the US dollar during the 1-day period ending at 10:00 AM ET on June 14th. Cryptaur has a total market capitalization of $0.00 and $255,998.00 worth of Cryptaur was traded on exchanges in the last 24 hours. Over the last seven days, Cryptaur has traded 2.4% higher against the US dollar. One Cryptaur token can now be purchased for $0.0042 or 0.00000065 BTC on popular cryptocurrency exchanges including HitBTC and LATOKEN.
- [By Joseph Griffin]
Camden Property Trust (NYSE:CPT) was upgraded by analysts at TheStreet from a “c+” rating to a “b-” rating in a report released on Thursday.
- [By Max Byerly]
Cryptaur (CURRENCY:CPT) traded up 3% against the US dollar during the 24 hour period ending at 0:00 AM E.T. on June 7th. One Cryptaur token can currently be bought for about $0.0042 or 0.00000055 BTC on exchanges including LATOKEN and HitBTC. Cryptaur has a total market capitalization of $0.00 and $115,915.00 worth of Cryptaur was traded on exchanges in the last 24 hours. Over the last week, Cryptaur has traded flat against the US dollar.
No comments:
Post a Comment